SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-24-001923
Filing Date
2024-02-20
Accepted
2024-02-20 08:33:49
Documents
20
Period of Report
2024-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 26327
2 AMENDMENT TO THE LICENSE AGREEMENT tenx_ex101.htm EX-10.1 37567
3 PRESS RELEASE tenx_ex991.htm EX-99.1 20410
9 tenx_ex991img2.gif GRAPHIC 631
10 tenx_ex991img3.jpg GRAPHIC 2879
  Complete submission text file 0001654954-24-001923.txt   226172

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tenx-20240219.xsd EX-101.SCH 5720
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20240219_lab.xml EX-101.LAB 14667
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20240219_cal.xml EX-101.CAL 898
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20240219_pre.xml EX-101.PRE 9275
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20240219_def.xml EX-101.DEF 2099
21 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3910
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 24650936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)